Barr Pharmaceuticals — Merger or Acquisition (July 2008)
29 slides from Barr Pharmaceuticals's merger presentation, Jul 21, 2008
Slide 1: Teva's Proposed Acquisition of Barr
Teva's Proposed Acquisition of Barr July 18, 2008
Slide 2: Bruce L. Downey, Chairman and Chief Executive Officer
Bruce L. Downey Chairman and Chief Executive Officer
Slide 3: Forward-Looking Statements
Forward-Looking Statements This communication contains "forward-looking statements" which represent the current expectations and beliefs of management of Barr Pharmaceuticals, Inc. (the "Company") concerning the proposed merger of the Company with Boron Acquisition Corp., a wholly-owned subsidiary o
Slide 4: Teva Offer to Acquire Barr
Approved by the Board of Directors of both companies Supported by Barr's senior management team Transaction anticipated to close by end of 2008 Teva Offer to Acquire Barr
Slide 5: Financial Terms of Transaction
Financial Terms of Transaction 100% of Barr shares for total cash and stock consideration of $7.46 billion Plus, assumption of net debt of $1.5 billion Each Barr share converted to $39.90 in cash and 0.6272 Teva ADRs Per share consideration equivalent to $66.50 as of July 17, 2008
Slide 6: Offer to Acquire Barr
Offer to Acquire Barr Reflects appreciation of the value of our vision and our historical success in building a highly successful specialty pharmaceutical company Recognizes value of Success in integrating the historic strengths of PLIVA into Barr Strong management of operations in more than 30 coun
Slide 7: Process to Close
Process to Close Successful close will require various approvals Hart-Scott-Rodino in the United States Governments/Regulators in select other countries Barr Shareholders From now through close both companies will operate separately Close expected by end of 2008
Slide 8: Acquisition Timeline
Acquisition Timeline July 18, 2008: Announcement July/August: SEC/Regulatory filings Hart-Scott-Rodino review October/November 2008: Mailing of Shareholder Proxy November/December 2008: Shareholder vote End of 2008: Anticipated closing
Slide 9: Rationale
Rationale Financial Strong business fundamentals in complementary geographies Exciting Global Growth Prospects both Product and Markets Generics Brands Biologics Minimal Overlap in Value and Volume Intangible World class capabilities to deliver affordable medicine globally Like-minded Management Leg
Slide 10: Strategic Fit Between Barr and Teva
Strategic Fit Between Barr and Teva Biologics Management Generics IP Legislative PIV Portfolio Teva brings: Broad Line Manufacturing Significant Global Scale Neuroscience, Specialty Pharma Tax Efficiency Barr brings: Niche Products Specialty Manufacturing Eastern & Central Europe Women's Healthcare
Slide 11: Barr & Teva Comparison
Barr & Teva Comparison Barr Teva Revenues $2.5 Billion $9.4 Billion R&D Budget $248 Million $581 Million U.S. Generic Portfolio 120 330 U.S. Proprietary Portfolio 27 3 Global Product Registrations (Pending) 700 3,000 Biopharmaceuticals Marketed 0 4 API Yes Yes Key Markets U.S., Germany, Croatia, Pol
Slide 12: Overview of Teva
Overview of Teva Vertically-integrated global pharmaceutical company founded in 1901 Three main business segments Finished Dosage Generic Pharmaceuticals Active Pharmaceutical Ingredients (API) Specialty Branded Pharmaceuticals Approximately 28,000 employees
Slide 13: Overview of Teva (cont'd)
Overview of Teva (cont'd) Direct presence in more than 60 countries Product distribution in 80+ countries 44 pharmaceutical manufacturing sites producing 50 billion doses 15 R&D centers 18 API manufacturing sites During 2007: 58% of sales in North America 25% in Western Europe (including Hungary) 17
Slide 14: Teva Operations
Teva Operations Missouri Netherlands Hungary Italy India Israel Mexico Switzerland NJ Puerto Rico Czech Republic China Peru Chile Argentina Venezuela Toronto CA PA UK Brazil
Slide 15: Barr North American Generic Business
120+ marketed products Products sold under Barr label Pure substitution model Majority are barrier-to-entry generic products, including women's healthcare and injectables Generic oral contraceptive portfolio totals 26 products Growing injectable portfolio Total of 7 products Expect to double portfol
Slide 16: Teva North American Generic Business
Teva North American Generic Business U.S. generic market leader Highest share in industry with over 12%* 330 marketed products Largest first-to-file / Paragraph IV pipeline Broad product portfolio, multiple capabilities Launched 25 products in 2007 Recent 2008 launches include Alendronate, Budeprion
Slide 17: Barr European and ROW Generic Business
Barr European and ROW Generic Business Key commercial markets are Croatia, Poland, Germany and Russia Portfolio of 1,025+ products representing 255 molecules Products compete in branded, generic and hybrid markets 1,300 sales and marketing representatives promote products Target physicians, pharmaci
Slide 18: Barr's Key European and ROW Markets
Barr's Key European and ROW Markets Germany Company's largest European market based on revenues Katadolon is company's largest selling product Company competes in both branded and branded-generic markets Croatia Company's second largest European market based on revenues European headquarters for Bar
Slide 19: Teva Europe
Teva Europe Direct presence in 24 countries Product distribution in 29+ countries 11 production centers 10 R&D centers 9,000 employees
Slide 20: Teva International Markets
Teva International Markets Israel, Mediterranean, Africa, Turkey Israel, Turkey, South Africa, Kenya, Nigeria, Cyprus, Malta, other African countries Central & Eastern Europe Bulgaria, Czech Republic, Estonia, Kazakhstan, Latvia, Lithuania, Poland, Romania, Russia, Slovakia, Ukraine, Uzbekistan Lati
Slide 21: Teva Market Positions in Europe
Teva Market Positions in Europe Retail market position - selected markets UK Italy Netherlands Germany France Spain Hungary Czech Poland Scandinavia Belgium Market leader Not in top 10 In top 3 In top 10 Legend
Slide 22: Barr Brand Products
Barr Brand Products 19 Non-Promoted Products Product Description Emergency contraceptive that can still prevent a pregnancy for up to 72 hours after contraceptive failure Flexible plastic intrauterine copper contraceptive that does not contain synthetic hormones Next generation extended-cycle oral c
Slide 23: Barr Brand Pipeline
Barr Brand Pipeline High value near term opportunities Four New Drug Applications (NDAs) awaiting approval at U.S. FDA Biologics License Application (BLA) for Adenovirus to be filed in mid-2008 Three projects in Phase III Robust programs in Phase I/II Actively developing products utilizing vaginal r
Slide 24: Teva Brand Products
Teva Brand Products Copaxone(r): Largest product and its first major innovative drug, is a leading multiple sclerosis ("MS") therapy Azilect(r): Second significant innovative drug, indicated for the treatment of Parkinson's disease
Slide 25: Teva Brand Pipeline
Teva Brand Pipeline 5 projects in Phase III Clinical Studies Products in various development stages in the areas of psoriasis, asthma, amyotrophic lateral sclerosis, Crohn's disease, lupus/lupus nephritis and oncology
Slide 26: Barr Biologics
Barr Biologics Several products in development including: Adenovirus with U.S. Department of Defense Expect to file BLA in U.S. in Q3 2008 G-CSF (Granulocyte Colony Stimulating Factor) for U.S. and Europe Half a dozen undisclosed products in various stages of development State-of-the-art development
Slide 27: Teva Biologics
Teva Biologics G-CSF, interferon alpha 2b, and hGH (human growth hormone) sold in limited number of markets Manufacturing facilities in Mexico, Hungary and China Bulk substance manufacturing facilities in Lithuania and China CoGenesys' biotechnology research team, technologies and innovative pipelin
Slide 28: Summary of Benefits
Summary of Benefits Combined Company will have: Annual revenues of approximately $11.9 billion 15.9% market share for all U.S. pharma companies 23.9% market share for all U.S. generic companies Operations in over 60 countries Leadership in the generic industry in number and success rate of patent ch
Slide 29: Teva's Proposed Acquisition of Barr
Teva's Proposed Acquisition of Barr July 18, 2008
Barr Pharmaceuticals — Merger or Acquisition (July 2008) on 6ix